Back to mobile site

Haemonetics (HAE) Tops Q3 EPS by 18c, Revenues Beat; Raises FY20 EPS Guidance Above Consensus

February 4, 2020 6:11 AM EST

Haemonetics (NYSE: HAE) reported Q3 EPS of $0.94, $0.18 better than the analyst estimate of $0.76. Revenue for the quarter came in at $259 million versus the consensus estimate of $255.4 million.

Q3 Earnings Letter PDF

GUIDANCE:

Haemonetics sees FY2020 EPS of $3.30-$3.40, versus the consensus of $3.18.

For earnings history and earnings-related data on Haemonetics (HAE) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Earnings, Guidance, Hot Guidance

Related Entities

Earnings